The Immunomodulatory Potential of Mesenchymal Stem Cells in a Retinal Inflammatory Environment
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
31863334
DOI
10.1007/s12015-019-09908-0
PII: 10.1007/s12015-019-09908-0
Knihovny.cz E-zdroje
- Klíčová slova
- Cytokines, Immunomodulation, Inflammation, Mesenchymal stem cells, Retina,
- MeSH
- antivirové látky farmakologie MeSH
- cytokiny metabolismus MeSH
- imunomodulace účinky léků imunologie MeSH
- interferon gama farmakologie MeSH
- interleukin-1beta farmakologie MeSH
- mediátory zánětu farmakologie MeSH
- mezenchymální kmenové buňky cytologie metabolismus MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- oxid dusnatý metabolismus MeSH
- retina cytologie účinky léků imunologie metabolismus MeSH
- TNF-alfa farmakologie MeSH
- zánět imunologie metabolismus patologie prevence a kontrola MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antivirové látky MeSH
- cytokiny MeSH
- IL1B protein, mouse MeSH Prohlížeč
- interferon gama MeSH
- interleukin-1beta MeSH
- mediátory zánětu MeSH
- oxid dusnatý MeSH
- TNF-alfa MeSH
Retinal degenerative disorders are characterized by a local upregulation of inflammatory factors, infiltration with cells of the immune system, a vascular dysfunction and by the damage of retinal cells. There is still a lack of treatment protocols for these diseases. Mesenchymal stem cell (MSC)-based therapy using immunoregulatory, regenerative and differentiating properties of MSCs offers a promising treatment option. In this study, we analyzed the immunomodulatory properties of mouse bone marrow-derived MSCs after their intravitreal delivery to the inflammatory environment in the eye, caused by the application of pro-inflammatory cytokines IL-1β, TNF-α and IFN-γ. The intravitreal administration of these cytokines induces an increased expression of pro-inflammatory molecules such as IL-1α, IL-6, inducible nitric oxide synthase, TNF-α and vascular endothelial growth factor in the retina. However, a significant decrease in the expression of genes for all these pro-inflammatory molecules was observed after the intravitreal injection of MSCs. We further showed that an increased infiltration of the retina with immune cells, mainly with macrophages, which was observed after pro-inflammatory cytokine application, was significantly reduced after the intravitreal application of MSCs. The similar immunosuppressive effects of MSCs were also demonstrated in vitro in cultures of cytokine-stimulated retinal explants and MSCs. Overall, the results show that intravitreal application of MSCs inhibits the early retinal inflammation caused by pro-inflammatory cytokines, and propose MSCs as a promising candidate for stem cell-based therapy of retinal degenerative diseases.
Zobrazit více v PubMed
Stem Cell Res Ther. 2013 Jun 04;4(3):65 PubMed
Tissue Eng. 2007 Jun;13(6):1185-95 PubMed
Clin Exp Immunol. 2011 Apr;164(1):1-8 PubMed
PLoS One. 2018 Aug 22;13(8):e0202156 PubMed
Arch Ophthalmol. 2010 Oct;128(10):1281-6 PubMed
Trends Immunol. 2015 Jun;36(6):354-63 PubMed
Stem Cell Rev Rep. 2013 Oct;9(5):609-19 PubMed
Invest Ophthalmol Vis Sci. 2009 Jan;50(1):273-80 PubMed
Mol Vis. 2006 May 10;12:467-77 PubMed
Stem Cells Dev. 2016 Jun 1;25(11):874-81 PubMed
Curr Eye Res. 2018 Apr;43(4):553-565 PubMed
Curr Eye Res. 2013 Sep;38(9):933-44 PubMed
J Exp Med. 2016 Feb 8;213(2):189-207 PubMed
PLoS One. 2018 Mar 27;13(3):e0194603 PubMed
Methods Mol Biol. 2019;1940:181-191 PubMed
J Leukoc Biol. 2007 Jun;81(6):1345-51 PubMed
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2862-70 PubMed
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27 PubMed
Cell Stem Cell. 2012 May 4;10(5):544-55 PubMed
J Cell Biochem. 2012 Feb;113(2):590-8 PubMed
Stem Cells. 2006 Dec;24(12):2868-76 PubMed
Stem Cell Res Ther. 2016 Jul 07;7(1):88 PubMed
Prog Retin Eye Res. 2013 May;34:19-48 PubMed
J Neurosci. 2003 Aug 27;23(21):7742-9 PubMed
Cytotherapy. 2016 Apr;18(4):487-96 PubMed
Cytokine. 2009 Apr;46(1):100-3 PubMed
Graefes Arch Clin Exp Ophthalmol. 2017 Aug;255(8):1581-1592 PubMed
Stem Cell Rev Rep. 2011 Jun;7(2):434-45 PubMed
Exp Eye Res. 2003 Apr;76(4):463-71 PubMed
Mediators Inflamm. 2015;2015:673090 PubMed
Cell Mol Life Sci. 2016 May;73(9):1765-86 PubMed
Immunol Lett. 2015 Dec;168(2):140-6 PubMed
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3742-8 PubMed
Biochem Biophys Res Commun. 2006 Jun 16;344(4):1071-9 PubMed
Stem Cells Dev. 2017 Oct 1;26(19):1399-1408 PubMed
Stem Cell Rev Rep. 2017 Oct;13(5):598-602 PubMed
Immunol Lett. 2007 Jun 15;110(2):91-100 PubMed
J Mol Histol. 2008 Apr;39(2):243-9 PubMed
J Diabetes Res. 2018 Apr 4;2018:8546423 PubMed
Cell Immunol. 2018 Apr;326:68-76 PubMed
Blood. 2004 Jun 15;103(12):4619-21 PubMed
Stem Cells Transl Med. 2015 Sep;4(9):1052-63 PubMed
Stem Cells Dev. 2014 Oct 15;23(20):2490-500 PubMed
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3767-3778 PubMed
Mol Vis. 2010 Jul 14;16:1304-16 PubMed
ALTEX. 2016;33(4):459-464 PubMed
Mol Biol Rep. 2013 Jun;40(6):3883-90 PubMed
The Immunomodulatory Effect of Silver Nanoparticles in a Retinal Inflammatory Environment
